Hosted on MSN1mon
PDS Biotech set for Phase 3 trial in HPV-positive cancer treatment
PRINCETON - PDS Biotechnology Corporation (NASDAQ:PDSB) has confirmed plans to commence its VERSATILE-003 Phase 3 clinical trial for a promising cancer immunotherapy within the first quarter of 2025.
Business Insider14d
PDS Biotech Initiates VERSATILE-003 Phase 3 Clinical Trial Evaluating Versamune® HPV in HPV16-Positive Head and Neck Cancer
PRINCETON, N.J., March 07, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq ... today announced the initiation of the VERSATILE-003 Phase 3 clinical trial. The trial is now open ...
Business Insider14d
PDS Biotechnology initiates VERSATILE-003 Phase 3 trial of Versamune HPV
PDS Biotechnology (PDSB) announced the initiation of the VERSATILE-003 Phase 3 clinical trial. The trial is now open to patient enrollment. VERSATILE-003 is a global, multi-center, randomized ...
Nasdaq14d
PDS Biotechnology Corporation Initiates VERSATILE-003 Phase 3 Clinical Trial for HPV16-Positive Head and Neck Cancer
PDS Biotech launches VERSATILE-003 Phase 3 trial to evaluate Versamune® HPV with pembrolizumab for treating HPV16-positive head and neck cancer. PDS Biotechnology Corporation has announced the ...
manilatimes14d
PDS Biotech Initiates VERSATILE-003 Phase 3 Clinical Trial Evaluating Versamune® HPV in HPV16-Positive Head and Neck Cancer
"Advancing into Phase 3 is a significant milestone in our mission to improve treatment options for patients with HPV16-positive recurrent/metastatic HNSCC,” noted Kirk Shepard, M.D., Chief Medical ...